Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The firm currently has a $60.00 price objective on the biotechnology company’s stock. Other analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated an overweight […]